Who is sponsoring NCT04939272?

NCT04939272 is sponsored by City of Hope Medical Center.

What drugs are being tested in NCT04939272?

Interventions in NCT04939272: Copanlisib Hydrochloride, Venetoclax.

What condition does NCT04939272 study?

NCT04939272 studies Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma.

Is NCT04939272 still recruiting?

NCT04939272 is currently active, enrolled. Last updated 1 May 2025.

Last reviewed 2025-05-01 · How we verify

NCT04939272

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Active, enrolled Phase 1, PHASE2 Last updated 1 May 2025

What this trial tests

Phase 1, PHASE2 trial testing Copanlisib Hydrochloride in Recurrent Mantle Cell Lymphoma in 8 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

29 June 2022

Primary endpoint
24 February 2026

24 February 2026

Quick facts

Lead sponsor	City of Hope Medical Center
Phase	Phase 1, PHASE2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	29 June 2022
Primary completion	24 February 2026
Estimated completion	24 February 2026
Sites	1 location across United States

Drugs / interventions tested

Copanlisib Hydrochloride — full drug profile →
Venetoclax (venetoclax) — full drug profile →

Conditions studied

Recurrent Mantle Cell Lymphoma — all drugs for Recurrent Mantle Cell Lymphoma →
Refractory Mantle Cell Lymphoma — all drugs for Refractory Mantle Cell Lymphoma →

Sponsor

City of Hope Medical Center

Who can join

18 and older, any sex, with Recurrent Mantle Cell Lymphoma or Refractory Mantle Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I/II trial studies the side effects, best dose, and effectiveness of copanlisib and venetoclax in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Copanlisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving copanlisib and venetoclax may help treat patients with mantle cell lymphoma.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Small-molecule agents for cancer immunotherapy.
Wang F, Fu K, Wang Y, Pan C, et al · · 2024 · cited 41× · PMID 38486980 · DOI 10.1016/j.apsb.2023.12.010
The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target.
Verzella D, Cornice J, Arboretto P, Vecchiotti D, et al · · 2022 · cited 23× · PMID 36140335 · DOI 10.3390/biomedicines10092233
Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers.
Shan KS, Bonano-Rios A, Theik NWY, Hussein A, et al · · 2024 · cited 19× · PMID 38396649 · DOI 10.3390/ijms25041973
Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.
Thus YJ, Eldering E, Kater AP, Spaargaren M. · · 2022 · cited 17× · PMID 35725771 · DOI 10.1038/s41375-022-01627-9
Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma.
Pang Y, Lu T, Xu-Monette ZY, Young KH. · · 2023 · cited 16× · PMID 36982568 · DOI 10.3390/ijms24065493
The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma.
Arun Kumar S, Gao J, Patel SA. · · 2023 · cited 12× · PMID 37672954 · DOI 10.1016/j.leukres.2023.107385
Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells.
Boccellato E, Comba L, Tavarozzi R, Castellino C, et al · · 2025 · cited 2× · PMID 40647536 · DOI 10.3390/cancers17132239

Verify or expand the search:

Other trials of Copanlisib Hydrochloride

Trials testing the same drug.

NCT05295589 — Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum R · Phase 2 · withdrawn
NCT04345913 — Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer · Phase 1, PHASE2 · active not recruiting
NCT04317105 — Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimuma · Phase 1, PHASE2 · active not recruiting
NCT03939897 — Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer · Phase 1 · active not recruiting
NCT03484819 — Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma o · Phase 2 · completed

Other recruiting trials for Recurrent Mantle Cell Lymphoma

Currently open trials in the same condition.

NCT07003295 — Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease R · Phase 2 · recruiting
NCT06675123 — Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lym · Phase 1 · recruiting
NCT06859008 — Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Rel · Phase 1 · recruiting
NCT06839053 — Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic L · Phase 2 · recruiting
NCT06191887 — B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide · Phase 1 · recruiting

Other City of Hope Medical Center trials

Trials by the same sponsor.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04939272 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
Last refreshed: 1 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04939272.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing